Fundraising FoxTranscera
Boston, US · Founded 2020 · 7 known investors
Find your way into Transcera
Sign up to see every warm intro you have to Transcera
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Transcera team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Transcera is a biotech company developing a new class of therapeutics that use lipid trafficking pathways to direct extracellular proteins into lysosomes for degradation, aimed at treating chronic diseases. Its platform combines a lysosome-targeting lipid, a chemical linker, and a peptide or protein binder to degrade soluble and membrane proteins across tissues.
Founders & leadership
Transcera was founded in 2020 by Wayne Lencer, Hunter Goble, and Justin Wolfe.
Investors · 7
How we know: funding news · pear.vc · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Portal Innovations's portfolio page · Not right? Tell us
How we know: Tau Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: board seat on SEC Form D · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$1M disclosed across 2 of 3 rounds · 2021–2023
▶$10KraisedNov 2021 · 1 investors · BiotechnologyRule 506(b)
- Wayne LencerExecutive Officer, Director
- Phil GrayeskiDirector
- William Hunter GobleExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $10K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1MraisedJul 2021 · 3 investors · BiotechnologyRule 506(b)
- Wayne LencerExecutive Officer, Director
- William Hunter GobleExecutive Officer, Director
- Phil GrayeskiDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Transcera do?
- Transcera is a biotech company developing a new class of therapeutics that use lipid trafficking pathways to direct extracellular proteins into lysosomes for degradation, aimed at treating chronic diseases. Its platform combines a lysosome-targeting lipid, a chemical linker, and a peptide or protein binder to degrade soluble and membrane proteins across tissues.
- Who founded Transcera?
- Transcera was founded by Wayne Lencer, Hunter Goble, Justin Wolfe in 2020.
- Who are Transcera's investors?
- Transcera's investors include Pear VC, Portal Innovations, Tau Ventures, Digitalis Ventures, KdT Ventures, TAU Ventures, Xora Innovation Pte Ltd.
- How much funding has Transcera raised?
- Transcera has disclosed $1M raised across 2 of its 3 known rounds.
- Where is Transcera headquartered?
- Transcera is headquartered in Boston, US.